My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$LECO {{ '2016-07-25T15:37:48+0000' | timeago}} • Webcast

Stanley Elliott of Stifel Nicolaus asks about the growth in Southeast Asia. $LECO said the growth is partly driven by investments in people and technologies in other regions around the world. The company is seeing some benefits from the technology center in Singapore. The long-term investment in the Indian market has also been favorable.

User Jacob Bareto {{ '2016-12-05T21:04:55+0000' | timeago}}

Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$

User Amy Lewis {{ '2016-12-05T19:53:36+0000' | timeago}}

Bad for $AAPL. Despite a 3% increase in wearables shipments as per IDC, Apple Watch shipments plunged a whopping 71%. Smartwatches doesn't seem to take the lead nowadays, basic wearables like $FIT appear to be reigning supreme.

User Jacqueline Gallardo {{ '2016-12-05T19:06:29+0000' | timeago}}

$CRM on the pop today.. big bubble.

User Johney Kingston {{ '2016-12-05T17:47:57+0000' | timeago}}

Slumping and down the drain... $HDSN. Flush out your holdings !

User Dawn Martis {{ '2016-12-05T16:59:46+0000' | timeago}}

$KITE I am loving this one... really flying like a kite today :-)

$TOL {{ '2016-12-06T12:14:08+0000' | timeago}} • Announcement

Home builder $TOL reported a drop in 4Q16 earnings due to higher costs and expenses as well as a rise in warranty charge primarily related to old stucco homes. Net income fell to $114.38MM or $0.67 per share from $147.16MM or $0.80 per share last year. Revenue grew to $1.86Bil from $1.44Bil.

$XRX {{ '2016-12-06T12:06:48+0000' | timeago}} • Announcement

$XRX appointed Joseph Echevarria, the former CEO of Deloitte LLP, and Cheryl Krongard, a former senior partner with Apollo Management LP, to its BoD effective Jan. 1, 2017. With these additions, $XRX Board will comprise 11 directors.

$CELG {{ '2016-12-06T12:03:36+0000' | timeago}} • Announcement

$CELG announced interim results from Abound clinical trial program evaluating use of Abraxane in patients with advanced non-small cell lung cancer (NSCLC). The study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in pivotal Phase 3 trial.

$PM {{ '2016-12-06T12:01:08+0000' | timeago}} • Announcement

$PM submitted on Dec. 5 a modified risk tobacco product (MRTP) application for its electronically heated tobacco product with the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products. $PM expects FDA to take minimum of 60 days to complete administrative review to determine whether to accept application for substantive review.

$JNJ {{ '2016-12-06T11:56:46+0000' | timeago}} • Announcement

Janssen Research & Development, a $JNJ company, said new Ibrutinib (Imbruvica) phase 2 data demonstrate promise in relapsed/refractory marginal zone lymphoma (MZL), a rare incurable type of non-hodgkin's lymphoma. Janssen said half of patients with relapsed/refractory MZL responded to ibrutinib.